Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when UNCY files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsUnicycive expands at-the-market offering by $50M to $150M total capacity
Filed June 5, 2026 · Period ending June 5, 2026 · ~1 min read
Key Changes
-
high
Company increased its at-the-market equity program from up to $100M to $150M, allowing it to sell an additional $50M of common stock into the market over time at prevailing prices through Guggenheim Securities.
Item 1.01 verify on EDGAR → -
medium
Filed new shelf registration statement with SEC to support the $50M expansion, providing legal framework to issue the additional shares to investors.
Item 9.01 verify on EDGAR → -
medium
Executed second amendment to sales agreement with Guggenheim Securities on June 5, 2026, formalizing the expanded offering terms.
Item 1.01 verify on EDGAR →
Summary
Unicycive Therapeutics expanded its at-the-market (ATM) equity offering program by 50%, increasing the total capacity from up to $100 million to $150 million. This gives the biotech company flexibility to raise an additional $50 million by selling shares directly into the market over time, rather than through a traditional one-time offering.
The company amended its existing sales agreement with Guggenheim Securities and filed a new shelf registration statement with the SEC to enable the expansion. For retail shareholders, this means potential dilution as the company can now issue more shares.
ATM offerings allow companies to raise capital opportunistically when stock prices are favorable, but they also increase the total share count, which dilutes existing ownership percentages. The expansion suggests Unicycive anticipates needing additional funding for its operations or clinical programs. Investors should watch for actual share sales under this expanded program in future quarterly filings (Form 10-Q) and monitor how the company deploys any capital raised. The timing and volume of sales will indicate management's view of current valuation and capital needs.
Section-by-Section Diff
Event · Item 9.01 — Financial Statements and Exhibits
Item 9.01 — Financial Statements and Exhibits filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Amendment No. 2 to Sales Agreement, dated June 5, 2026, between Unicycive Therapeutics, Inc. and Guggenheim Securities, LLC
The company executed a second amendment to its at-the-market (ATM) sales agreement with Guggenheim Securities. ATM agreements allow companies to sell shares directly into the market over time rather than in a single offering. The specific terms of this amendment are not disclosed in the 8-K itself but are incorporated by reference to the S-3 shelf registration statement filed the same day.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify